Overview
Macroglobulinemic nephropathy results from elevated levels of monoclonal immunoglobulins (paraproteins) that impair renal function, often seen in patients with macroglobulinemia. 1Diagnosis
Measure blood and plasma viscosity at +32°C to +37°C to assess rheological impact 1.
Evaluate red cell concentration alongside paraprotein levels for comprehensive viscosity assessment 1.
Utilize sensitive alpha 2-macroglobulin assays for biomarker analysis, though specificity for native vs. modified forms is not differentiated 2.Management
Target paraprotein reduction with chemotherapy regimens such as rituximab-based treatments (specific doses not detailed in abstracts) 1.
Monitor and manage blood viscosity, particularly at low shear rates, to alleviate symptoms related to impaired blood flow 1.
Consider supportive care measures to manage renal complications, though specific interventions are not detailed in provided abstracts 1.Special Populations
No specific guidance provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 12.Key Recommendations
Assess blood viscosity at +32°C to +37°C, incorporating red cell concentration, for optimal diagnosis and symptom correlation in macroglobulinaemia patients (Evidence: Moderate) 1.
Employ sensitive alpha 2-macroglobulin assays for monitoring disease progression, acknowledging limitations in distinguishing between different forms of alpha 2-macroglobulin (Evidence: Weak) 2.
Prioritize treatment aimed at reducing paraprotein levels to mitigate renal and rheological complications, though specific dosing recommendations are not provided (Evidence: Expert opinion) 1.References
1 Persson SU, Larsson H, Odeberg H. How should blood rheology be measured in macroglobulinaemia?. Scandinavian journal of clinical and laboratory investigation 1998. link
2 Slot LA, Hendil KB. Alpha 2-macroglobulin: fast and sensitive analysis with monoclonal antibodies. Scandinavian journal of clinical and laboratory investigation 1987. link